{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T00:33:08Z","timestamp":1794357188326,"version":"4.9.0"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81700044"],"award-info":[{"award-number":["81700044"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Huanhua talents project","award":["2022ZYXK2011011"],"award-info":[{"award-number":["2022ZYXK2011011"]}]},{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["2022YFS0108"],"award-info":[{"award-number":["2022YFS0108"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Open Research Fund of State Key Laboratory of southwestern Chinese Medicine Resources","award":["SKLTCM2022019"],"award-info":[{"award-number":["SKLTCM2022019"]}]},{"name":"Sichuan Provincial Care Health Commitee Technology Program","award":["2021-205"],"award-info":[{"award-number":["2021-205"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejmech.2025.117804","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T10:47:02Z","timestamp":1748083622000},"page":"117804","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Research progress of ATR small molecule inhibitors in cancer therapy"],"prefix":"10.1016","volume":"296","author":[{"given":"Shujin","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiumei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aili","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1026-0282","authenticated-orcid":false,"given":"Jianyou","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117804_bib1","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cell.2017.01.002","article-title":"Endogenous DNA damage as a source of genomic instability in cancer","volume":"168","author":"Tubbs","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.117804_bib2","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a012559","article-title":"DNA base damage by reactive oxygen species, oxidizing agents, and UV radiation","volume":"5","author":"Cadet","year":"2013","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.ejmech.2025.117804_bib3","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1042\/BST20180519","article-title":"Carcinogens and DNA damage","volume":"46","author":"Barnes","year":"2018","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.ejmech.2025.117804_bib4","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nature07943","article-title":"The cancer genome","volume":"458","author":"Stratton","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117804_bib5","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3390\/cancers12041050","article-title":"DNA damage\/repair management in cancers","volume":"12","author":"Alhmoud","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2025.117804_bib6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13045-022-01360-x","article-title":"The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.117804_bib7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","article-title":"State-of-the-art strategies for targeting the DNA damage response in cancer","volume":"16","author":"Pili\u00e9","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.117804_bib8","doi-asserted-by":"crossref","first-page":"7749","DOI":"10.1038\/sj.onc.1210880","article-title":"ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks","volume":"26","author":"Lavin","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.117804_bib9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2897","article-title":"Causes and consequences of replication stress","volume":"16","author":"Zeman","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.117804_bib10","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1017\/erm.2020.3","article-title":"DNA damage checkpoint kinases in cancer","volume":"22","author":"Smith","year":"2020","journal-title":"Expet Rev. Mol. Med."},{"key":"10.1016\/j.ejmech.2025.117804_bib11","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1158\/2159-8290.CD-17-1461","article-title":"Mechanisms of oncogene-induced replication stress: jigsaw falling into place","volume":"8","author":"Kotsantis","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2025.117804_bib12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41573-022-00558-5","article-title":"Targeting replication stress in cancer therapy","volume":"22","author":"da Costa","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.117804_bib13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ccr.2006.11.024","article-title":"p53-deficient cells rely on ATM- and ATR-Mediated checkpoint signaling through the p38MAPK\/MK2 pathway for survival after DNA damage","volume":"11","author":"Reinhardt","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2025.117804_bib14","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/sj.bjc.6604208","article-title":"G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer","volume":"98","author":"Bucher","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.117804_bib15","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.3390\/cancers13143415","article-title":"Intersection of two checkpoints: could inhibiting the DNA damage response checkpoint rescue immune checkpoint-refractory cancer?","volume":"13","author":"Goff","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2025.117804_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcaa024","article-title":"Regulation and pharmacological targeting of RAD51 in cancer","volume":"2","author":"Grundy","year":"2020","journal-title":"NAR Cancer"},{"key":"10.1016\/j.ejmech.2025.117804_bib17","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1016\/j.molcel.2022.05.004","article-title":"Hallmarks of DNA replication stress","volume":"82","author":"Saxena","year":"2022","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2025.117804_bib18","article-title":"Targeting the DNA damage response in cancer","volume":"5","author":"Federica","year":"2024","journal-title":"MedComm"},{"key":"10.1016\/j.ejmech.2025.117804_bib19","doi-asserted-by":"crossref","first-page":"262","DOI":"10.31083\/j.fbl2907262","article-title":"SMARCA2 and SMARCA4 participate in DNA damage repair","volume":"29","author":"Yu","year":"2024","journal-title":"Front. Biosci. (Landmark Ed.)"},{"key":"10.1016\/j.ejmech.2025.117804_bib20","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-15-0945","article-title":"ATM mutations in cancer: therapeutic implications","volume":"15","author":"Choi","year":"2016","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.117804_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107450","article-title":"Targeting ATR as cancer therapy: a new era for synthetic lethality and synergistic combinations?","volume":"207","author":"Bradbury","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2025.117804_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116804","article-title":"An update on small molecule compounds targeting synthetic lethality for cancer therapy","volume":"278","author":"Luo","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117804_bib23","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/ijc.28226","article-title":"Roles of Chk1 in cell biology and cancer therapy","volume":"134","author":"Zhang","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.117804_bib24","article-title":"Functions and inhibitors of CHK1 in cancer therapy","volume":"22","year":"2024","journal-title":"Med. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.117804_bib25","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.3390\/cells12101387","article-title":"The p38\/MK2 pathway functions as Chk1-backup downstream of ATM\/ATR in G2-checkpoint activation in cells exposed to ionizing radiation","volume":"12","author":"Luo","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2025.117804_bib26","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1111\/cas.15845","article-title":"Emerging strategies for cancer therapy by ATR inhibitors","volume":"114","author":"Yano","year":"2023","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2025.117804_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103662","article-title":"Targeting ATM and ATR for cancer therapeutics: inhibitors in clinic","volume":"28","author":"Priya","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2025.117804_bib28","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1073\/pnas.93.7.2850","article-title":"cDNA cloning and gene mapping of a candidate human cell cycle checkpoint protein","volume":"93","author":"Cimprich","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2025.117804_bib29","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2023.2237209","article-title":"Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK)","volume":"38","author":"Huang","year":"2023","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117804_bib30","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","article-title":"ATM and ATR as therapeutic targets in cancer","volume":"149","author":"Weber","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2025.117804_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2021.100017","article-title":"Progress towards a clinically-successful ATR inhibitor for cancer therapy","volume":"2","author":"Barnieh","year":"2021","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.117804_bib32","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.3390\/ph3051311","article-title":"Prospects for the use of ATR inhibitors to treat cancer","volume":"3","author":"Wagner","year":"2010","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2025.117804_bib33","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1126\/science.1083430","article-title":"Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes","volume":"300","author":"Zou","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.117804_bib34","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.sbi.2019.12.010","article-title":"Structures and regulations of ATM and ATR, master kinases in genome integrity","volume":"61","author":"Williams","year":"2020","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.ejmech.2025.117804_bib35","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/cr.2017.158","article-title":"Cryo-EM structure of human ATR-ATRIP complex","volume":"28","author":"Rao","year":"2018","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2025.117804_bib36","first-page":"1538","article-title":"Structural and strategic landscape of PIKK protein family and their inhibitors: an overview","volume":"25","author":"Angira","year":"2020","journal-title":"FBL"},{"key":"10.1016\/j.ejmech.2025.117804_bib37","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.3390\/molecules27082491","article-title":"Recent advances in synergistic antitumor effects exploited from the inhibition of ataxia telangiectasia and RAD3-related protein kinase (ATR)","volume":"27","author":"Wang","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.117804_bib38","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.pbiomolbio.2019.06.003","article-title":"Structural insights into the critical DNA damage sensors DNA-PKcs, ATM and ATR","volume":"147","author":"Baretic","year":"2019","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.117804_bib39","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.pbiomolbio.2020.10.009","article-title":"Structural basis of the (in)activity of the apical DNA damage response kinases ATM, ATR and DNA-PKcs","volume":"163","author":"Jansma","year":"2021","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.117804_bib40","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1128\/MCB.02238-06","article-title":"Function of a conserved checkpoint recruitment domain in ATRIP proteins","volume":"27","author":"Ball","year":"2007","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.117804_bib41","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.tibs.2010.09.005","article-title":"ATR: a master conductor of cellular responses to DNA replication stress","volume":"36","author":"Flynn","year":"2011","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejmech.2025.117804_bib42","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2174\/156800961603160206122927","article-title":"Small molecules targeting ataxia telangiectasia and Rad3-related (ATR) kinase: an emerging way to enhance existing cancer therapy","volume":"16","author":"Andrs","year":"2016","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.ejmech.2025.117804_bib43","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.dnarep.2004.03.032","article-title":"Dial 9\u20131\u20131 for DNA damage: the Rad9\u2013Hus1\u2013Rad1 (9\u20131\u20131) clamp complex","volume":"3","author":"Parrilla-Castellar","year":"2004","journal-title":"DNA Repair"},{"key":"10.1016\/j.ejmech.2025.117804_bib44","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.cell.2005.12.041","article-title":"TopBP1 activates the ATR-ATRIP complex","volume":"124","author":"Kumagai","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.117804_bib45","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrm2450","article-title":"ATR: an essential regulator of genome integrity","volume":"9","author":"Cimprich","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.117804_bib46","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/cancers9050041","article-title":"Targeting the ATR-CHK1 axis in cancer therapy","volume":"9","author":"Rundle","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2025.117804_bib47","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.jmb.2017.04.006","article-title":"Rationally designed PI3K\u03b1 mutants to mimic ATR and their use to understand binding specificity of ATR inhibitors","volume":"429","author":"Lu","year":"2017","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.117804_bib48","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1021\/acs.jmedchem.3c01917","article-title":"Discovery of the potent and selective ATR inhibitor camonsertib (RP-3500)","volume":"67","author":"Black","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117804_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/s41416-023-02436-2","article-title":"A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours","author":"Burris","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.117804_bib50","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/s41591-023-02399-0","article-title":"Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results","volume":"29","author":"Yap","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2025.117804_bib51","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/jnci\/djae098","article-title":"Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)","volume":"116","author":"Fontana","year":"2024","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejmech.2025.117804_bib52","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","article-title":"The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage\u2013inducing or repair\u2013compromising therapies in preclinical cancer models","volume":"19","author":"Wengner","year":"2020","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.117804_bib53","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2025.117804_bib54","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00280-024-04745-6","article-title":"Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406)","volume":"95","author":"Krishnamurthy","year":"2025","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117804_bib55","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s13046-024-03143-3","article-title":"The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer","volume":"43","author":"Lee","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117804_bib56","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-23-0402","article-title":"The novel ATR inhibitor M1774 induces replication protein overexpression and broad synergy with DNA-targeted anticancer drugs","author":"Jo","year":"2024","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.117804_bib57","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/bjh.19218","article-title":"The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib","volume":"204","author":"Sartori","year":"2024","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2025.117804_bib58","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1158\/1535-7163.MCT-23-0094","article-title":"Elimusertib has antitumor activity in preclinical patient-derived pediatric solid tumor models","volume":"23","author":"Pusch","year":"2024","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.117804_bib59","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/cncr.35059","article-title":"Biomarker-driven phase 2 umbrella trial: clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer","volume":"130","author":"Park","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2025.117804_bib60","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-24-0013","article-title":"Novel combinations of immunotherapies or DNA damage repair inhibitors in platinum-refractory extensive-stage small cell lung cancer: the phase II BALTIC study","volume":"30","author":"Reinmuth","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117804_bib61","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41591-024-02808-y","article-title":"Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial","volume":"30","author":"Besse","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2025.117804_bib62","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.18632\/oncotarget.2158","article-title":"Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970","volume":"5","author":"Hall","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.117804_bib63","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/s41416-021-01406-w","article-title":"Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours","volume":"125","author":"Shapiro","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.117804_bib64","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00280-020-04184-z","article-title":"Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types","volume":"87","author":"Terranova","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117804_bib65","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41416-021-01405-x","article-title":"Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine \u00b1 cisplatin in patients with advanced solid tumours","volume":"125","author":"Middleton","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.117804_bib66","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1470-2045(20)30180-7","article-title":"Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Konstantinopoulos","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2025.117804_bib67","article-title":"Randomized phase II study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: final overall survival and biomarker analyses","volume":"8","author":"Konstantinopoulos","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejmech.2025.117804_bib68","doi-asserted-by":"crossref","unstructured":"M. Alrooqi, S. Khan, F.A. Alhumaydhi, S.A. Asiri, M. Alshamrani, M.M. Mashraqi, A. Alzamami, A.M. Alshahrani, A.A. Aldahish, A therapeutic journey of pyridine-based heterocyclic compounds as potent anticancer agents: a review (from 2017 to 2021), Anti Cancer Agents Med. Chem. 22 (n.d.) 2775\u20132787. https:\/\/doi.org\/10.2174\/1871520622666220324102849.","DOI":"10.2174\/1871520622666220324102849"},{"key":"10.1016\/j.ejmech.2025.117804_bib69","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1158\/1538-7445.AM2022-2588","article-title":"Abstract 2588: M1774, a novel potent and selective ATR inhibitor, shows antitumor effects as monotherapy and in combination","volume":"82","author":"Zimmermann","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117804_bib70","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-23-2409","article-title":"First-in-Human study of the Ataxia Telangiectasia and Rad3-related (ATR) inhibitor Tuvusertib (M1774) as monotherapy in patients with solid tumors","author":"Yap","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117804_bib71","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1158\/1535-7163.MCT-20-1026","article-title":"Novel and highly potent ATR inhibitor M4344 kills cancer cells with replication stress, and enhances the chemotherapeutic activity of widely used DNA damaging agents","volume":"20","author":"Jo","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.117804_bib72","series-title":"Atr Inhibitors and Uses Thereof","author":"Shan","year":"2023"},{"key":"10.1016\/j.ejmech.2025.117804_bib73","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.3c01917","article-title":"Discovery of the potent and selective ATR inhibitor camonsertib (RP-3500)","author":"Black","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117804_bib74","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/1535-7163.MCT-21-0615","article-title":"RP-3500: a novel, potent, and selective ATR inhibitor that is effective in preclinical models as a monotherapy and in combination with PARP inhibitors","volume":"21","author":"Roulston","year":"2022","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.117804_bib75","series-title":"ATR Inhibitors and Uses Thereof","author":"Gao","year":"2023"},{"key":"10.1016\/j.ejmech.2025.117804_bib76","series-title":"Pyrazole-Containing Derivative, Pharmaceutically Acceptable Salt Thereof, Preparation Method Therefor and Application Thereof","author":"Zhou","year":"2023"},{"key":"10.1016\/j.ejmech.2025.117804_bib77","series-title":"Triheterocyclic Derivative, and Pharmaceutical Composition and Application Thereof","author":"Liu","year":"2022"},{"key":"10.1016\/j.ejmech.2025.117804_bib78","series-title":"Sulfoximine-Containing Atr Inhibitor Compound","author":"Zhang","year":"2023"},{"key":"10.1016\/j.ejmech.2025.117804_bib79","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1021\/acs.jmedchem.0c00369","article-title":"Damage incorporated: discovery of the potent, highly selective, orally available ATR inhibitor BAY 1895344 with favorable pharmacokinetic properties and promising efficacy in monotherapy and in combination treatments in preclinical tumor models","volume":"63","author":"L\u00fccking","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117804_bib80","series-title":"Bis-Heterocyclic Compounds and their Use as ATR Inhibitors","author":"Huang","year":"2023"},{"key":"10.1016\/j.ejmech.2025.117804_bib81","series-title":"Naphthyridine Derivative as Atr Inhibitor and Method for Preparing Same","author":"Xie","year":"2024"},{"key":"10.1016\/j.ejmech.2025.117804_bib82","series-title":"Class of 1,7-naphthyridine Compounds and Application Thereof","author":"Wang","year":"2022"},{"key":"10.1016\/j.ejmech.2025.117804_bib83","series-title":"Naphthyridine Derivative and Use Thereof","author":"Zhang","year":"2023"},{"key":"10.1016\/j.ejmech.2025.117804_bib84","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1021\/jm301859s","article-title":"Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy in Vivo Antitumor Activity","volume":"56","author":"Foote","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117804_bib85","doi-asserted-by":"crossref","first-page":"9889","DOI":"10.1021\/acs.jmedchem.8b01187","article-title":"Discovery and characterization of AZD6738, a potent inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) kinase with application as an anticancer agent","volume":"61","author":"Foote","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117804_bib86","series-title":"Atr Inhibitors and Uses Thereof","author":"Shan","year":"2022"},{"key":"10.1016\/j.ejmech.2025.117804_bib87","doi-asserted-by":"crossref","first-page":"21890","DOI":"10.1021\/acs.jmedchem.4c01595","article-title":"Discovery of ART0380, a potent and selective ATR kinase inhibitor undergoing phase 2 clinical studies for the treatment of advanced or metastatic solid cancers","volume":"67","author":"Carroll","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117804_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114945","article-title":"Discovery of novel 7,7-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidines as ATR inhibitors based on structure-based drug design","volume":"246","author":"Qi","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117804_bib89","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.3390\/molecules28114521","article-title":"Design, synthesis, and biological evaluation of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3-related (ATR) kinase for the efficient treatment of cancer","volume":"28","author":"Shao","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.117804_bib90","series-title":"Tetrahydropyridopyrimidine Derivative and Application Thereof","author":"Yang","year":"2023"},{"key":"10.1016\/j.ejmech.2025.117804_bib91","series-title":"Tricyclic Heterocyclic Derivative as Well as Pharmaceutical Composition and Application Thereof","author":"Tang","year":"2022"},{"key":"10.1016\/j.ejmech.2025.117804_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128651","article-title":"Discovery of 6,7-dihydro-5H-pyrrolo[3,4-d] pyrimidine derivatives as a new class of ATR inhibitors","volume":"63","author":"Chen","year":"2022","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.117804_bib93","series-title":"Fused Pyrimidine Derivative and Application Thereof","author":"Zhao","year":"2023"},{"key":"10.1016\/j.ejmech.2025.117804_bib94","doi-asserted-by":"crossref","first-page":"12735","DOI":"10.1021\/acs.jmedchem.4c00734","article-title":"Discovery of preclinical candidate AD1058 as a highly potent, selective, and brain-penetrant ATR inhibitor for the treatment of advanced malignancies","volume":"67","author":"Liu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117804_bib95","series-title":"Atr Inhibitor and Use Thereof","author":"Xiang","year":"2022"},{"key":"10.1016\/j.ejmech.2025.117804_bib96","series-title":"Pyrazolopyrimidine Compound Used as Atr Kinase Inhibitor","author":"Cheng","year":"2023"},{"key":"10.1016\/j.ejmech.2025.117804_bib97","series-title":"New Type Pyrazolopyrimidine Compound and Composition Thereof","author":"Xiao","year":"2023"},{"key":"10.1016\/j.ejmech.2025.117804_bib98","series-title":"Bimorpholine-Substituted Heterocyclic Compound and Medical Application Thereof","author":"Cheng","year":"2023"},{"key":"10.1016\/j.ejmech.2025.117804_bib99","series-title":"Substituted Fused Heterocyclic Compound, and Preparation Method Therefor and Use Thereof, WO2023116594A1","author":"Long","year":"2023"},{"key":"10.1016\/j.ejmech.2025.117804_bib100","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1021\/jm501026z","article-title":"Phosphatidylinositol 3-Kinase (PI3K) and phosphatidylinositol 3-Kinase-Related kinase (PIKK) inhibitors: importance of the morpholine ring","volume":"58","author":"Andrs","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117804_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115370","article-title":"Discovery of thieno[3,2-d]pyrimidine derivatives as potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) kinase","volume":"255","author":"Duan","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117804_bib102","series-title":"Pyrimidine Fused Ring Compound and Derivative, Preparation Method, Pharmaceutical Composition and Application Thereof","author":"Chen","year":"2023"},{"key":"10.1016\/j.ejmech.2025.117804_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106535","article-title":"Design, synthesis, and biological evaluation of pyrido[3,2-d]pyrimidine derivatives as novel ATR inhibitors","volume":"136","author":"Duan","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.117804_bib104","series-title":"Condensed ring pyrimidine compound as well as preparation method, pharmaceutical composition and application thereof","author":"Chen","year":"2023"},{"key":"10.1016\/j.ejmech.2025.117804_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114187","article-title":"Discovery of a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase: structural activity relationship and antitumor activity both in vitro and in vivo","volume":"232","author":"Bin","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117804_bib106","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1021\/jm101488z","article-title":"Discovery of potent and selective inhibitors of Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents","volume":"54","author":"Charrier","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117804_bib107","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1021\/acs.jmedchem.9b00426","volume":"62","author":"Knegtel","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117804_bib108","series-title":"Compound as Atr Kinase Inhibitor","author":"Peng","year":"2023"},{"key":"10.1016\/j.ejmech.2025.117804_bib109","series-title":"Pyrazinone Derivative as Well as Preparation and Application Thereof","author":"Wang","year":"2022"},{"key":"10.1016\/j.ejmech.2025.117804_bib110","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cbpa.2019.11.012","article-title":"Targeted protein degradation: current and future challenges","volume":"56","author":"Hanzl","year":"2020","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117804_bib111","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.2147\/IJN.S448684","article-title":"Nano-proteolysis targeting chimeras (nano-PROTACs) in cancer therapy","volume":"19","author":"Song","year":"2024","journal-title":"IJN"},{"key":"10.1016\/j.ejmech.2025.117804_bib112","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.707317","article-title":"E3 ligase ligands in successful PROTACs: an overview of syntheses and linker attachment points","volume":"9","author":"Bricelj","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2025.117804_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116159","article-title":"Discovery of the first ataxia telangiectasia and Rad3-related (ATR) degraders for cancer treatment","volume":"267","author":"Huang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117804_bib114","article-title":"Discovery of selective and potent ATR degrader for exploration its kinase-independent functions in acute myeloid leukemia cells","volume":"63","author":"Wang","year":"2024","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2025.117804_bib115","series-title":"3-aminopyrazine-2-formamide Targeted Protein Hydrolysis Chimera as Well as Preparation Method, Pharmaceutical Composition and Application of 3-aminopyrazine-2-formamide Targeted Protein Hydrolysis Chimera","author":"Ma","year":"2023"},{"key":"10.1016\/j.ejmech.2025.117804_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116167","article-title":"Design, synthesis, and biological characterization of proteolysis targeting chimera (PROTACs) for the ataxia telangiectasia and RAD3-related (ATR) kinase","volume":"267","author":"Alfayomy","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117804_bib117","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrm.2017.67","article-title":"The essential kinase ATR: ensuring faithful duplication of a challenging genome","volume":"18","author":"Saldivar","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.117804_bib118","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.pbiomolbio.2020.11.005","article-title":"Roles of ATM and ATR in DNA double strand breaks and replication stress","volume":"161","author":"Williams","year":"2021","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.117804_bib119","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41573-024-01060-w","article-title":"DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications","volume":"24","author":"Drew","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.117804_bib120","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.chembiol.2003.09.002","article-title":"The process of structure-based drug design","volume":"10","author":"Anderson","year":"2003","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117804_bib121","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13045-019-0733-6","article-title":"Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand","volume":"12","author":"Mei","year":"2019","journal-title":"J. Hematol. Oncol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425005690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425005690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T14:11:12Z","timestamp":1762265472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425005690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":121,"alternative-id":["S0223523425005690"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117804","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Research progress of ATR small molecule inhibitors in cancer therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117804","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117804"}}